IRIS
AIMARETTI, Gianluca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.131
NA - Nord America 5.127
AS - Asia 1.110
Continente sconosciuto - Info sul continente non disponibili 23
SA - Sud America 23
OC - Oceania 8
AF - Africa 4
Totale 12.426
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.093
IE - Irlanda 2.166
DE - Germania 957
SE - Svezia 882
UA - Ucraina 777
IT - Italia 700
CN - Cina 511
FI - Finlandia 435
HK - Hong Kong 239
IN - India 171
FR - Francia 77
VN - Vietnam 77
GB - Regno Unito 56
IR - Iran 51
CA - Canada 34
NL - Olanda 32
EU - Europa 23
BE - Belgio 22
TR - Turchia 14
BR - Brasile 13
PK - Pakistan 9
AU - Australia 8
JP - Giappone 8
KR - Corea 7
MY - Malesia 7
GR - Grecia 4
IL - Israele 4
MO - Macao, regione amministrativa speciale della Cina 4
PE - Perù 4
PH - Filippine 4
RO - Romania 4
RU - Federazione Russa 4
CL - Cile 3
TH - Thailandia 3
AR - Argentina 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
ES - Italia 2
PT - Portogallo 2
RS - Serbia 2
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
KE - Kenya 1
KW - Kuwait 1
ME - Montenegro 1
MK - Macedonia 1
NO - Norvegia 1
PL - Polonia 1
SN - Senegal 1
TG - Togo 1
Totale 12.426
Salva come PNG Salva come JPEG
Città #
Dublin 2.159
Jacksonville 1.476
Dearborn 696
Wilmington 432
Chandler 289
Lawrence 275
Princeton 275
Hong Kong 229
San Mateo 215
Beijing 214
Andover 157
Ann Arbor 152
Ashburn 121
Piemonte 105
Bremen 99
Dong Ket 74
Turin 52
Milan 51
Hefei 46
Norwalk 40
Houston 38
Düsseldorf 37
Philadelphia 36
Kunming 35
Novara 35
Boardman 32
Nanjing 30
Fairfield 29
Helsinki 28
Woodbridge 24
Torino 23
Zanjan 22
Nanchang 21
Brussels 20
Cassano Magnago 19
Monmouth Junction 19
Paris 19
Leawood 17
Toronto 17
Alessandria 15
Jinan 15
Dronten 14
Kocaeli 13
Rome 13
Guangzhou 12
Zhengzhou 12
Ardabil 11
West Jordan 10
Bologna 9
Chennai 9
Fuzhou 9
Shenyang 9
Augusta 8
Grafing 8
Montreal 8
Seattle 8
São Paulo 8
Borgo Vercelli 7
Sham Shui Po 7
Sydney 7
Berlin 6
Hebei 6
Naples 6
Shaoxing 6
Wuhan 6
Baotou 5
Napoli 5
Nardò 5
Palermo 5
Strasbourg 5
Xian 5
Cambridge 4
Changsha 4
Dallas 4
Lima 4
Macao 4
New York 4
Pescantina 4
Redwood City 4
San Diego 4
Senigallia 4
Shanghai 4
Tehran 4
Trivero 4
Vercelli 4
Winnipeg 4
Athens 3
Bangkok 3
Bari 3
Bien Hoa 3
Busanjin-gu 3
Casalecchio Di Reno 3
Chengdu 3
Cuggiono 3
Goyang-si 3
Gunzenhausen 3
Hangzhou 3
Henderson 3
Ipoh 3
Mülheim 3
Totale 8.032
Salva come PNG Salva come JPEG
Nome #
Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study 192
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 137
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 94
Molecular analysis of the Growth Hormone Releasing Hormone Receptor (GHRH-R) gene in Isolated Growth Hormone Deficiency (IGHD): identification of a likely etiological mutation in the signal peptide. 90
Change over time of COVID-19 hospital presentation in Northern Italy 89
Evaluation of the short-term effects of dietary supplement “Flebotrofine” on markers of endothelial dysfunction in type 2 diabetes patients: a pilot study. 87
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 87
Autophagy and thyroid carcinogenesis: genetic and epigenetic links 83
Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. 82
Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy 82
Identification of Haptoglobin as a Readout of rhGH Therapy in GH Deficiency 82
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency. 77
Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. 76
Effects of phenylalanine, histidine, and leucine on basal and GHRH-stimulated GH secretion and on PRL, insulin, and glucose levels in short children. Comparison with the effects of arginine. 75
Influence of UV radiation on the association between 25-hydroxy vitamin D levels and cardiovascular risk factors in obesity. 74
Acute Vitamin D₃ Supplementation in Severe Obesity: Evaluation of Multimeric Adiponectin 71
Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients 70
Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test. 69
MOLECULAR ANALYSIS OF THE GROWTH HORMONE GENE IN ISOLATED GROWTH HORMONE DEFICIENCY: POSSIBILE INVOLVEMENT OF A PROMOTER POLYMORPHISM 68
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 68
Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights 68
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. 67
Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life 67
Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS) 66
How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings? 66
Thyroid cancer phenotypes in relation to inflammation and autoimmunity 64
Transsphenoidal surgery for pituitary adenomas: early results from a single center 64
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. 63
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. 63
Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism 63
Appropriate use of stimulation tests and insulin-like growth factor-I in obesity 63
GHRH an GH secretagogues: clinical perspectives and safety. 63
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group 62
New approach to the diagnosis of growth hormone deficiency in adults. 61
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. 60
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 60
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 60
PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. 60
Unacylated, acylated ghrelin and obestatin levels are differently inhibited by oral glucose load in pediatric obesity: Association with insulin sensitivity and metabolic alterations. 60
IGF-I levels in different conditions of low somatotrope secretion in adulthood: obesity in comparison with GH deficiency. 59
Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood. 59
Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome 59
Ghrelin gene polymorphisms and ghrelin, insulin, IGF-I, leptin and anthropometric data in children and adolescents 58
DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacement. 58
One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. 58
Effects of Growth Hormone (GH) Therapy Withdrawal on Glucose Metabolism in Not Confirmed GH Deficient Adolescents at Final Height. 58
Embolization for Insulinoma in Complicated Severe Obesity: Description of an Inoperable Case and Review of the Literature 58
Ovotesticular Disorder of Sex Development: A Rare Case of Lateral Subtype 45X/46XY kariotype Diagnosed in Adulthood 58
Targeting microbiota in dietary obesity management: a systematic review on randomized control trials in adults 57
GHRH plus arginine in the diagnosis of acquired GH deficiency of childhood-onset. 57
Adrenal sensitivity to ACTH1-24 as function of age, body weight and pituitary function. 57
Clinical picture and the treatment of TBI-induced hypopituitarism 57
THE RELATIONSHIP BETWEEN CORTISOL AND IGF-I INFLUENCES METABOLIC ALTERATION IN PEDIATRIC OVERWEIGHT AND OBESITY 57
Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy 57
Unusual metastases from tall cell variant of papillary thyroid cancer 56
Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory 56
Acylated and unacylated ghrelin levels in normal weight and obese children: influence of puberty and relationship with insulin, leptin and adiponectin levels. 56
IGF-I levels in prepubertal and pubertal children with Down syndrome. 55
Serum leptin levels are not influenced by arginine and insulin infusion and by acute changes of GH. 55
Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA. 55
GHRELIN CONCENTRATIONS IN NORMAL AND OBESE CHILDREN: ROLE OF PUBERTY. 54
Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease 54
The impact of the metabolic phenotype on thyroid function in obesity 54
Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiency. 54
Low dose orally administered arginine is able to enhance both basLow dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. 54
Plasma Oxytocin Concentration in Pre- and Postmenopausal Women: Its Relationship with Obesity, Body Composition and Metabolic Variables 54
Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. 53
Inherent insulin sensitivity is a major determinant of multimeric adiponectin responsiveness to short-term weight loss in extreme obesity 53
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group 53
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. 52
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. 52
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. 52
Measurement of Height Velocity is an useful marker for monitoring pituitary function in patients who had traumatic brain injury. 52
Circulating adipokines and metabolic setting in differentiated thyroid cancer 52
Effectiveness of E-learning training on drug – dosage calculation skills of nursing students: A randomized controlled trial 52
Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases 52
The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency 51
A novel compound heterozygous mutation of the aromatase gene in an adult man: new insight into the role of estrogen on gonadal development. 51
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19 51
GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine. 50
Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span. 50
Metabolic alterations in patients who develop Traumatic Brain Injury (TBI)-induced hypopituitarism. 50
Circulating angiopoietin-like 8 (ANGPTL8) is a marker of liver steatosis and is negatively regulated by Prader-Willi Syndrome 50
Vitamin D and neurological diseases: An endocrine view 50
Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach 50
High-end normal adrenocorticotropic hormone and cortisol levels are associated with specific cardiovascular risk factors in pediatric obesity: a cross-sectional study. 50
The lullaby of the sun: the role of vitamin D in sleep disturbance 50
Vitamin D as a Biomarker of Ill Health among the Over-50s: A Systematic Review of Cohort Studies. 50
Preface 49
Quality of life, mood disturbances and psychological parameters in adult patients with GH deficiency. 49
Non-surgical ablative therapies for inoperable benign insulinoma 49
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE) 49
Serum uric acid potentially links metabolic health to measures of fuel use in lean and obese individuals 48
Aging and comorbidities influence the risk of hospitalization and mortality in diabetic patients experiencing severe hypoglycemia 48
Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. 47
Lymphocytes and immunoglobulin patterns across the threshold of severe obesity 47
Levothyroxine Replacement in Obese Adults: The Role of Metabolic Variables and Aging on Thyroid Testing Abnormalities 47
Systematic review of ghrelin response to food intake in pediatric age, from neonates to adolescents. 47
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo 47
Ghrelin and synthetic GH secretagogues. 46
Totale 6.176
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.517
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201918 0 0 0 0 0 0 0 0 0 0 6 12
2019/20202.688 12 7 249 18 436 430 628 117 297 227 264 3
2020/20211.883 254 2 260 6 256 76 280 10 279 49 297 114
2021/20221.909 69 39 305 196 114 25 184 40 137 38 358 404
2022/20233.777 311 176 188 74 226 259 104 128 2.063 31 129 88
2023/20241.033 97 96 75 29 250 43 285 71 23 44 20 0
Totale 12.731